Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Matuzumab + Pemetrexed in 2nd Line Advanced NSCLC
NCT00111839Phase 2Completed
- Sponsor
- EMD Serono
- Start
- May 2005
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of matuzumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by EMD Serono. Primary endpoint: Objective Response Rate. Started May 2005; status: completed.
02
Drugs
matuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00111839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111839.